We read with interest the article by Gupta and colleagues describing
their findings in an investigation of the utility loss associated with
glaucoma. When considered in light of previous investigations this work
makes an important contribution to our limited understanding of the
influence of culture, socio-economic status, and ethnic background on
health state preference. It is particularly gratifying...
We read with interest the article by Gupta and colleagues describing
their findings in an investigation of the utility loss associated with
glaucoma. When considered in light of previous investigations this work
makes an important contribution to our limited understanding of the
influence of culture, socio-economic status, and ethnic background on
health state preference. It is particularly gratifying to see this done in
glaucoma, a disease where there has been very limited work done towards
utility estimate.
There are some aspects of the results of this study that bear
clarification. First, we ask that they comment on staging glaucoma using
visual acuity rather than visual field loss. Clinical staging of glaucoma
by loss of visual field is the method preferred by glaucoma specialists,[1]
and both utility loss (as measured by the EQ-5D)[2] and cost of care[3] have
been shown to be responsive to this measure. Second, it would be good to
report the number of study participants who refused to trade any time (or
risk blindness or death due to surgery). In previous work, this proportion
has substantial.[4] Finally, we ask that they comment more fully what some
may consider an inconsistency in the findings. They found that on average
people with glaucoma are willing to accept a 14% risk of death to
eliminate their disease, but only a 3% risk of blindness, leading us to
assume that among the people in this sample, being blind is worse than
being dead. This has not been found in previous studies of the utility
associated with blindness.
Just as Dr. Gupta and his colleagues speculate that there might be a
cultural or socio-economic basis for the substantially higher utility loss
associated with glaucoma he found in his sample (when contrasted with the
work of Jampel4), it is possible that these apparently “inconsistent”
findings might be the result of differing views of visual disability in
our industrialized society (with nearly universal access to—although not
necessarily utilization of—health care and rehabilitative services),
versus that found in a developing country. If these findings are indeed
valid and supported by additional research, it would make an important
contribution to our understanding of preference based measures by
providing evidence that preferences for health states (and thus variance
in reported utility) may vary based upon socio-economic factors. While
some have suggested that this is not the case,[5] such a finding would be
consistent with recent reports that reported utility varies by race and
other factors.[6,7]
References:
1. Hodapp E, Parrish RK, Anderson DR. Clinical Decisions in Glaucoma.
St. Louis: Mosby, 1993.
2. Alm A, Kobelt G, Bergstrom A, Chen E, Linden C. Measuring Utility in
Glaucoma. 2005 Annual Meeting Association for Research in Vision and
Ophthalmology Fort Lauderdale, Florida.
3. Lee PP, Walt J, Doyle JJ, Kotak SV, Evans SJ, Budenz DL, et al. A Multi
-center, Retrospective Pilot Study of Resource Utilization and Costs
Associated with Severity of Disease in Glaucoma. Archives of Ophthalmology
2005;Accepted for Publication.
4. Jampel HD, Schwartz A, Pollack I, Abrams D, Weiss H, Miller R. Glaucoma
Patients' Assessment of Their Visual Function and Quality of Life. Journal
of Glaucoma 2002;11(2):154-63.
5. Brown GC, Brown MM, Sharma S, Beauchamp GR, Hollands H. The
reproducibility of ophthalmic utility values. Transactions of the American
Ophthamological Society 2001;99:199-204.
6. Bravata DM, Nelson LM, Garber AM, Goldstein MK. Invariance and
Inconsistency in Utility Ratings. Medical Decision Making 2005;25(2):158-
67.
7. Wittenberg E, Divi N, Halpern E, Araki SS, Prosser L, Weeks JC. The
Effect of Age, Race and Gender on Utility Values for Hypothetical Health
States. 2004 Annual Meeting Society for Medical Decision Making Atlanta
Georgia.
We read with interest the letter by Prakash et al.[1] concerning
residual cortical lens matter in the anterior chamber after
phacoemulsification. This was noted ten days post-operatively and was
promptly removed to alleviate a secondary rise in intraocular pressure
(IOP). We would like to share our experience of an unusual case of
retained lens matter presenting thirteen months post phacoemulsif...
We read with interest the letter by Prakash et al.[1] concerning
residual cortical lens matter in the anterior chamber after
phacoemulsification. This was noted ten days post-operatively and was
promptly removed to alleviate a secondary rise in intraocular pressure
(IOP). We would like to share our experience of an unusual case of
retained lens matter presenting thirteen months post phacoemulsification.
A 77-year old male patient presented with slight blurring of vision
and photophobia in the right eye, thirteen months after undergoing
uncomplicated phacoemulsification with posterior chamber intraocular lens
implantation (Acrysof SA60). His visual acuity was 6/12 in this right eye
and he had 1+ cells in the anterior chamber with no evidence of synechiae
and a normal IOP. Posterior segment examination was unremarkable. A
presumptive diagnosis of recurrent post-operative uveitis was made and he
was treated with a course of topical corticosteroids. However, at his
follow up visit three weeks later, his condition had not improved.
Examination now revealed corneal oedema localized inferiorly and a small
piece of residual nuclear lens matter was now evident in the anterior
chamber, which had not been noted initially. This fragment of 1 mm by 1mm in size was seen lodged between the inferior iris and the cornea. A day
later it was surgically removed under topical anaesthesia. Two weeks later
the visual acuity had improved to 6/9 and the corneal oedema as well as
the anterior chamber activity had resolved completely.
Retained nuclear or cortical lens matter after phacoemulsification
tends to present in the first few weeks following surgery and can cause a
more pronounced uveitis, corneal oedema, intraocular pressure rise and/or
cystoid macula oedema.[2] However, presentation although rare has been
reported as late as 5 months postoperatively.[3] To our knowledge, this is
the first case to present with this specific complication 13 months
postoperatively. We presume the mechanism to be initial entrapment of the
residual lens matter in the ciliary sulcus at a very peripheral location.
This would be followed by gradual migration of the fragment towards the
pupil facilitated by iris contraction/dilation movements and eventually
into the anterior chamber giving rise to symptoms. Meticulous technique
and a careful survey for any retained lens material at the time of surgery
is essential in preventing such complications. One must also consider this
possibility in post operative patients presenting with recurrent uveitis
even many months after the initial operation.
References
1. Prakash G, Kumar A, Purohit A. Unusual case of residual cortical
lens matter in anterior chamber. Br J Ophthalmol. 2003 Nov;87(11):1421.
2. Coombes A and Gartry D. Postoperative complications. In: Cataract
Surgery 1st ed. BMJ, 2003:168,172.
3. Bohigian GM, Wexler SA.Complications of retained nuclear fragments in
the anterior chamber after phacoemulsification with posterior chamber lens
implant. Am J Ophthalmol. 1997 Apr;123(4):546-7.
We read with interest the recently published paper by Manzano et al.
titled ‘Inhibition of experimental corneal neovascularisation by
bevacizumab (Avastin)’. The authors used topical eyedrop application of
either saline or bevacizumab in a rat model of corneal neovascularization,
with apparent moderate success. Furthermore, in their discussion, they
mention that there was incomplete inhibition of th...
We read with interest the recently published paper by Manzano et al.
titled ‘Inhibition of experimental corneal neovascularisation by
bevacizumab (Avastin)’. The authors used topical eyedrop application of
either saline or bevacizumab in a rat model of corneal neovascularization,
with apparent moderate success. Furthermore, in their discussion, they
mention that there was incomplete inhibition of the neovascularization and
speculate several other cytokines or growth factors may be responsible.
However, bevacizumab has previously been reported to be incapable of
binding rodent VEGF [2]. The findings in this study suggest that either
there is in fact a low affinity interaction with bevacizumab and rat VEGF,
or the effects observed are due to other non-VEGF mediated interactions of
bevacizumab. If the latter is the case, then the question arises as to
whether this interaction is specific to bevacizumab or can be replicated
with other type specific normal IgG. Recently Gerber et al. reported the
generation of transgenic mice producing humanized VEGF-A [1], which
produce a VEGF protein that, in contrast to wild type mouse protein, does
bind bevacizumab. This mouse would be suitable for evaluating human
specific anti-VEGF therapies in vivo. We anticipate Lucentis will be
evaluated in this new model and await the results eagerly.
References
1. Gerber, H.P., Wu, X., Yu, L., Wiesmann, C., Liang, X.H., Lee,
C.V., Fuh, G., Olsson, C., Damico, L., Xie, D., Meng, Y.G., Gutierrez, J.,
Corpuz, R., Li, B., Hall, L., Rangell, L., Ferrando, R., Lowman, H.,
Peale, F., and Ferrara, N., Mice expressing a humanized form of VEGF-A may
provide insights into the safety and efficacy of anti-VEGF antibodies.
Proc Natl Acad Sci U S A, 2007. 104(9): p. 3478-83.
2. Lin, Y.S., Nguyen, C., Mendoza, J.L., Escandon, E., Fei, D., Meng,
Y.G., and Modi, N.B., Preclinical pharmacokinetics, interspecies scaling,
and tissue distribution of a humanized monoclonal antibody against
vascular endothelial growth factor. J Pharmacol Exp Ther, 1999. 288(1): p.
371-8.
We thank Drs Hanovar and Ali for their comments. The main impetus for
publishing this data was to show that children are NOT prone to infections
with this strategy. In fact while steroid injections were given in cases
of severe corneal neovascularisation such as K.I.D. syndrome and
ectodermal hypoplasia , the fact that no child got a canaliculitis or
other infection even when steroids were used, re-affirms that infection i...
We thank Drs Hanovar and Ali for their comments. The main impetus for
publishing this data was to show that children are NOT prone to infections
with this strategy. In fact while steroid injections were given in cases
of severe corneal neovascularisation such as K.I.D. syndrome and
ectodermal hypoplasia , the fact that no child got a canaliculitis or
other infection even when steroids were used, re-affirms that infection is
not a risk that should prevent the clinician from using silicone punctal
plugs if appropriate.
Furthermore , clinically if spontaneous extrusion occurred after 6 months
we often found that the symptoms had improved. We really wanted to know if
using the plugs was a redundant manouevre , hence discussing the rate of
extrusion within 6 months of placement , which we considered to be high in
any case ( 19%).
Perhaps the most striking fact is that we were unable to cite any other
article dedicated to children with respect to the use of punctal plugs .
We hope this article will encourage Drs Ali and Hanovar and others to
share their experiences.
We read with interest the article by Kapetanakis et al.[1] The
authors presented a systemic review of published population-based surveys
to provide estimates of global and regional prevalence of primary open-
angle glaucoma (POAG). The authors claimed that this review provided the
most precise estimates of POAG prevalence thus far, as they adopted a more
"inclusive" approach, compared to previous re...
We read with interest the article by Kapetanakis et al.[1] The
authors presented a systemic review of published population-based surveys
to provide estimates of global and regional prevalence of primary open-
angle glaucoma (POAG). The authors claimed that this review provided the
most precise estimates of POAG prevalence thus far, as they adopted a more
"inclusive" approach, compared to previous review.[2] As a result of this
inclusive approach, more publications were included in this review with
greater total number of cases and participants, and thus the authors
believed that these estimates provided greater certainty compared to
previous reviews.[2 3]
Nevertheless, while an 'inclusive' approach adopted in this review
generated a 'seemingly' more precise estimate (slightly narrower credible
intervals), it may not necessarily provide estimates which 'accurately'
reflect the trends of POAG prevalence. This is mainly because, the review
also included older studies with improper definition/ diagnosis of POAG
which used raised IOP (i.e. greater than 21mmHg) as a key diagnostic
criterion for POAG. It has been widely recognized that using IOP as a
diagnostic criterion is not appropriate and may miss POAG cases with lower
levels of IOP.[4] This point has also been reiterated and acknowledged by
the authors themselves in the manuscript. Furthermore, in Table 2, the
authors showed that reliance on IOP in POAG diagnosis was associated with
lower POAG prevalence. This finding befittingly concurs with the point
that studies which used IOP as a diagnostic criterion would indeed
underestimate the prevalence of POAG. Thus, inclusion of older studies
with improper POAG definition in the meta-analysis would naturally result
in an underestimated overall pooled estimate despite having a seemingly
narrower range of credible intervals (mainly due to higher number of POAG
cases). This is evident when comparing the global POAG prevalence in this
review (2.2%) with the prevalence estimated in our group's recent meta-
analysis project (3.05%).[2]
The idea to include more studies in order to have 'greater power' but
at the expense of compromised study quality inclusion criteria, is
fundamentally flawed in the context of conducting a reliable meta-
analysis. Estimation errors caused by inclusion of poor quality studies
may not be sufficiently accounted for by using modeling method to adjust
for study design factor. Thus, the authors' claim that 'more precise and
accurate estimates were produced in this review' appears to be
unconvincing and overly stated.
Secondly, response rate was not taken into account when identifying
studies to be included in this meta-analysis. It was noticed that studies
of low response rates (i.e. less than 60% or 70%) were also included in
the analysis. It should be noted that population-based studies with
suboptimal response rate can give rise to sampling bias even though random
sampling method was adopted. Thus, estimates from these studies may not be
accurately representative of their respective underlying populations.
Inclusion of such studies may further introduce error to the overall
pooled estimate. Furthermore, if greater weights were attributed by
studies which relied on IOP diagnostic criterion or by studies with poor
response rate in this meta-analysis, the impact on the overall pooled
estimate would be even greater. With regards to this, a forest plot ought
to be included in this meta-analysis to illustrate the effect size and the
weight rendered by each study. Such illustration with additional
sensitivity analyses (stratified by study design factors or response rate)
may help to further validate or refute the approach adopted in this
analysis.
Taken together, we humbly opine that a more 'inclusive' approach but
without adequate screening of study quality, may not necessarily yield
more accurate estimates. The seemingly more precise estimate (i.e.
slightly narrower credible intervals) was simply due to increase in sheer
number of POAG cases from studies of inadequate quality. Robust and
comprehensive assessments of study quality are central to a valid, high
quality meta-analysis.
Thank you.
References:
1. Kapetanakis VV, Chan MP, Foster PJ, et al. Global variations and
time trends in the prevalence of primary open angle glaucoma (POAG): a
systematic review and meta-analysis. Br J Ophthalmol 2015.
2. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and
projections of glaucoma burden through 2040: a systematic review and meta-
analysis. Ophthalmology 2014;121(11):2081-90.
3. Quigley HA, Broman AT. The number of people with glaucoma
worldwide in 2010 and 2020. Br J Ophthalmol 2006;90(3):262-7.
4. Quigley HA. Glaucoma. Lancet (London, England) 2011;377(9774):1367
-77.
The authors of this article (Tan J C H, and Hitchings R. Non-penetrating
glaucoma surgery: the state of play. Br J Ophthalmol 2001;85:234-237) should be commended on attempting to tackle this issue. Nevertheless we do feel that their fundamental points and principal arguments merit reconsideration.
The authors state categorically that "long term outcomes do not exit
for the newer...
The authors of this article (Tan J C H, and Hitchings R. Non-penetrating
glaucoma surgery: the state of play. Br J Ophthalmol 2001;85:234-237) should be commended on attempting to tackle this issue. Nevertheless we do feel that their fundamental points and principal arguments merit reconsideration.
The authors state categorically that "long term outcomes do not exit
for the newer non-penetrating surgery technique" when in fact long term
(43.2 months +/- 14.3 (SD)) results for deep sclerectomy with collagen
implant have been presented to the European Glaucoma Society (EGS)
Glaucoma Symposium, 2000, and have also been published some time ago.[1] The
study provided a qualified success rate of 94.8% and the complete success
rate, 61.9% after 60 months (survival analysis), with a mean IOP at end of
follow-up of 11.8 +/- 3. The study reported no surgically induced cataract
of the whole series of 105 patients.
The authors, unfortunately, failed to cite a landmark study[2]
comparing deep sclerectomy without an implant to trabeculectomy in the two
eyes of the same patient in a prospective randomised fashion. At 12
months, mean IOP reduction was 12.3 +/- 4.2 (sclerectomy) versus 14.1 +/-
6.4 mmHg (trabeculectomy) (P = 0.15), and an IOP Furthermore the authors cite a study by Gandolfi as personal
communication supposedly providing evidence that "trabeculectomy produces
lower and better sustained IOP control than either viscocanalostomy or
deep sclerectomy". The authors fail to mention however, that in this
particular study postoperative YAG goniopunctures were considered as a
failure criteria. Excluding goniopuncture from the success criteria would
easily be compared to considering laser suture lysis or even YAG
capsulotomies to be failure criteria of glaucoma or cataract surgeries.
Furthermore Gandolfi concluded that Deep sclerectomy was associated with
lower perturbation of lens nuclear transparency (personal communication,
January 2002).
In another point worthy of reconsideration the authors site a study [3]
that allegedly draws attention to high rates of hypotony and hyphaema
after intraoperative conversion of deep sclerectomy to trabeculectomy
following accidental intraopeartive perforation of the trabeculo-
Descemet's membrane (TDM). However the authors again fail to mention, when
quoting this specific study, that "when deep sclerectomy is complicated
with a perforation of the TDM, the long term success rate of the surgery
is similar to that of trabeculectomy". This conclusion would encourage the
surgeons to start their surgery as a deep sclerectomy, knowing that in
case of a perforation and a subsequent transformation to trabeculectomy,
the chances of success would be similar to initial trabeculectomy.
The authors of the paper at hand compare in their figures
viscocanalostomy, deep scelerectomy without an implant, deep sclerectomy
with collagen implant, and deep sclerectomy without suturing the
superficial flap to each other, and thus drawing certain conclusions. The
different techniques have one thing in common, the element of non-
perforation. It is not useful to compare apples and pears.
A major factor in the conflicting, often contradictory, results
available is the element of long learning curves.
As an example one group reported 0% success rate in their first series of
viscocanalostomy patients [4] and then presented their second series with a
success rate of 15%.[5]
The same group also analyzed the depth of their dissection of the
deep sclera [6] to find that they dissected too superficially in 48% of their
cases and too deeply in 17%. Meaning that the proper depth of dissection,
which should bisect transversally the Schlemm's canal deroofing it, was
not achieved in the majority of their cases.
To achieve successful non-penetrating surgery, the dissection of the deep sclerectomy needs to be correct. This entails a total excision of
corneal stroma behind Descemet's membrane and the excision of the inner
wall of Schlemm's canal and the juxtacanalicular trabeculum. An implant
has to be used to maintain the scleral space patent.[7] Laser goniopuncture
should be performed at any postoperative stage when IOP mounts beyond the
target pressure.
We do however wholeheartedly agree with the authors on the importance of
conducting a large-scale multinational randomised prospective trial as the
only possible method to compare non-penetrating glaucoma surgery, or any
other new surgical practice, to trabeculectomy.
Tarek Shaarawy1, MD and André Mermoud2, MD
1. Head Glaucoma unit, Memorial Research Institute of Ophthalmology, Giza,
Egypt.
2. Head Glaucoma unit, University of Lausanne, Switzerland.
References
(1) Shaarawy T, Karlen M, Schnyder C, Achache F, Sanchez E, Mermoud
A. Five-year results of deep sclerectomy with collagen implant. J Cataract Refract Surg 2001;27:1770-8.
(2) El Sayyad F, Helal M, El Kholify H, Khalil M, El Maghraby A.
Nonpenetrating deep sclerectomy versus trabeculectomy in bilateral primary
open-angle glaucoma. Ophthalmology 2000;107:1671-4.
(3) Sanchez E, Schnyder CC, Mermoud A. [Comparative results of deep
sclerectomy transformed to trabeculectomy and classical trabeculectomy].
Klin Monatsbl Augenheilkd 1997;210:261-4.
(4) Jonescu-Cuypers C, Jacobi P, Konen W, Krieglstein G. Primary viscocanalostomy versus trabeculectomy in white patients with open-angle
glaucoma: A randomized clinical trial. Ophthalmology 2001;108:254-8.
(5) Dietlein, T. S. and Krieglstein, G. K. Morphology and pressure-
reducing efficacy after viscocanalostomy. 23. 2001. Paris, European
Glaucoma Society. Closed Meeting of the European Glaucoma Society.
(6) Dietlein TS, Luke C, Jacobi PC, Konen W, Krieglstein GK. Variability
of dissection depth in deep sclerectomy: morphological analysis of the
deep scleral flap. Graefes Arch Clin Exp Ophthalmol 2000;238:405-9.
(7) Shaarawy, T., Nguyen Chr, Schnyder, C., Achache, F., and Mermoud, A.
Comparative study between deep sclerectomy with and without collagen
implant: Long term follow-up. Invest Ophthalmol42(4), S544. 2001.
I should like to congratulate the authors for the article citing
the original publication on peripheral fading by Troxler (1804).
However, as editor of the website on the work of the Swiss
philosopher Ignaz Paul Vital Troxler (1780-1866) who started as physician
and ophthalmologist before engaging in research on anthropological and
political subjects, I regret that after 201 years, the publication of 18...
I should like to congratulate the authors for the article citing
the original publication on peripheral fading by Troxler (1804).
However, as editor of the website on the work of the Swiss
philosopher Ignaz Paul Vital Troxler (1780-1866) who started as physician
and ophthalmologist before engaging in research on anthropological and
political subjects, I regret that after 201 years, the publication of 1804 is often cited in an incomplete and/or misleading way.
Troxler used to sign his publications in the world's first
ophthalmological journal (i.e. "Ophthalmologische Bibliothek", edited by
K. Himly and J.A.Schmidt) with "D." for "doctor". Therefore,the fact that
the early neurophysiologist and neuropsychologist "D.Troxler" and the
political philosopher I.P.V.Troxler are identical has often been overlooked
in the medical literature, despite the fact that Troxler's concept of
perception has had an important impact on the development of modern
neuropsychological research.
I should like to suggest that, in references to "Über das
Verschwinden gegebener Gegenstände innerhalb unseres Gesichtskreises" (On
the disappearance of given objects from our visual field), the author be
cited as "Troxler D.(I.P.V.)", to facilitate identification.
I kindly invite you to visit the website
http://www.troxlerforum.ch which contains a biographical summary, a bibliography and some references on research related to Troxler's works on visual perception.
Sincerely Yours,
Hans U. Iselin M.D. CH-4310 Rheinfelden
(Switzerland)
I read with great interest your case report on the leech bite to the eye sustained by a 4 year old girl in Germany - in particular that
infestation of the human eye is very rare (“To our knowledge only one case
is described in the literature”). While this may indeed be the case in
Europe, here in Tasmania, the southernmost state of Australia, this event
is evidently much more common and occasions a lot...
I read with great interest your case report on the leech bite to the eye sustained by a 4 year old girl in Germany - in particular that
infestation of the human eye is very rare (“To our knowledge only one case
is described in the literature”). While this may indeed be the case in
Europe, here in Tasmania, the southernmost state of Australia, this event
is evidently much more common and occasions a lot less excitement on the
part of health professionals.
My experience of this occurred in January 2004 as I was bushwalking
in the Cradle Mountain- Lake St Clair National Park. Leeches are quite
common in the Tasmanian bush. They are land leeches and in some places in
wet conditions can be in plague proportions. However in dry summer
weather they are relatively uncommon. On the 5th day of our walk my
daughter and I were climbing a pass at 1100 metres in a snowstorm when a
flurry of snow blew into my right eye and with it something dark and
rather large. When I couldn’t readily dislodge it, I called my daughter
over and she identified it as a leech, very firmly attached and biting
through the white of my eye.
The recommended ways of detaching leeches are to either apply salt or
a flame, but we had no salt with us and had no intention of applying a
flame near the eye. I toyed with the idea of using a solution of fruit
saline to the eye, but wasn’t sure exactly what was in it and was loathe
to risk harm to the eye with an unknown substance. The other way of
getting rid of leeches is to irritate them with a gentle rubbing motion
until they drop off - one is always counselled not to just pull them off.
None of these options seemed possible. In a matter of minutes the
leech had inveigled itself so that only its head was visible at the inner
corner of my eye, its tail just visible at the outer corner and its body
totally inaccessible up under my upper eyelid. I briefly entertained the
notion of letting it stay there until it had fed and dropped off, but its
proximity to my tear duct began to worry me, given the speed with which it
had already made itself at home. In the end I irritated it until it
detached its back end and once I got a fair grip on it made one of those
split second decisions - and yanked.
The eye bled profusely and I packed it with snow. However, as we
dropped to lower altitudes, snow was no longer available and bleeding
recommenced. By the time I reached a hut that afternoon the tissue around
the eye was noticeably swollen and the eye itself was very bloodshot. The
next morning (Monday) it looked worse rather than better so we set off
to walk the 32 kilometres north to the nearest road, in order to get the
eye seen to as soon as possible. We acquired salt from another walker and
I bathed the eye with a saline solution several times during the day, in
an effort to avoid infection. We got out of the bush by midday on Tuesday,
but by the time we had driven the 400km to Hobart it was evening so
doctors and ophthalmologists were largely unavailable and I ended up
seeing a locum general practitioner at an After Hours clinic. He was new
to Tasmania and hadn’t seen a similar case, so he conferred with the
casualty section of the local hospital, but they really just confirmed his
initial advice to me.
We all agreed there appeared to be no vision problems involved. If I
had cared to queue up at the hospital for 3-4 hours I could have been
checked out for corneal erosion, but I didn’t bother as the doctor and I
were both pretty sure I didn’t have any. The doctor assured me that the
subconjunctival bleeding (the white of my eye was entirely red) would
disappear in 2 -3 weeks and in the event it took only 5 days for it to do
so. As I was planning to return to the bush almost immediately I was
prescribed Chloromycetin eye ointment to use in the event of the eye
becoming infected, which didn’t occur. I was told that there was no need
to see an eye specialist as there was nothing they could do.
Having been largely reassured by this visit, I thought I’d just check
out the internet with leech/bite/eye where, amongst others, I found your
journal reference and thought you might be interested in a related
experience.
We have read Manzano et al’s insightful paper[1] with interest and appreciated the comments concerning the inhibitory effects of bevacizumab on corneal neovascularisation (NV). However, the manuscript had some important aspects that need to be clarified. Cumulative data from numerous basic and clinical studies strongly implicates the central role of VEGF in ocular and corneal angiogenesis. Binding all free-ci...
We have read Manzano et al’s insightful paper[1] with interest and appreciated the comments concerning the inhibitory effects of bevacizumab on corneal neovascularisation (NV). However, the manuscript had some important aspects that need to be clarified. Cumulative data from numerous basic and clinical studies strongly implicates the central role of VEGF in ocular and corneal angiogenesis. Binding all free-circulating VEGF by specific antibodies inhibits VEGF-mediated receptor stimulation which normally leads to an abnormal angiogenesis in pathological conditions.[2,3] Bevacizumab (Avastin) is a humanised version of a monoclonal parent antibody originally produced in mice specifically against human VEGF. Since the parent antibody of avastin is a murine protein likely to provoke an immune response and thus unsuitable for use in humans, it has been humanised by genetic engineering to overcome these disadvantages. The humanisation process turns the parent antibody into commercially available avastin molecule, 93% human and 7% murine. However, the specificity of avastin molecule is exactly similar to that of the parent antibody, which binds to human VEGF with a high affinity, but has “no effect on host VEGF” (i.e., that produced by the mouse).[4] This is why preclinical anti-tumor studies of both avastin and its parent antibody have been conducted on human xenografts model in animals, and complete inhibition of tumor growth was not seen (and would not be expected) due to the interfering effects of host VEGF, which is not inhibited by the anti-human VEGF antibody, avastin.[5] Our previous case report [6] demonstrated that bevacizumab, a humanized anti-VEGF antibody, may actually have a therapeutic option for corneal NV in human beings. However, bevacizumab should not reasonably be considered to serve as an antiangiogenic agent in rat corneal tissue for the inherited characteristics of this molecule explained in detail above. Furthermore, we have previously tested this hypothesis in a similar (unpublished) pilot study of silver nitrate induced corneal NV in rats, but on the contrary found no improvement on the degree of corneal NV after intraperitoneal injection of bevacizumab 5 mg/kg, equivalent to its effective intravenous dose applied for the treatment of human colorectal cancers. Therefore, it is problematic to select such a monoclonal anti-human VEGF antibody, as an anti-rat VEGF agent in any experimental study conducted in rats. So, we unfortunately consider that this is a major methodological error in this experimental study.
The possible explanation for the difference encountered in the extent of corneal NV after topically applied avastin in rat eyes could be an unexpected cross-reaction of bevacizumab molecule with rat VEGF. We think that cross-reactivity of human specific monoclonal recombinant antibodies (if such exists), particularly bevacizumab, with other murine subspecies is another interesting topic of extensive researches. Another, but a minor concern in this paper is about the dose of topically applied avastin, yet not explained by the authors how to determine 2 drops of avastin 4mg/ml (i.e, approximately corresponding to 0.4 mg/day) solution daily would be sufficient for inhibiting corneal NV, since its minimal intravitreal dose is 1.25 mg in clinical practice, and also bioavailability of topically applied avastin drops in the cauterized corneal tissue has not been established. Finally, we obviously support the suggestion of using anti-human VEGF agents for prevention and management of corneal NV in the clinical practice [6], yet consider this experimental research has a major methodological error.
References
1. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-7.
3. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000;41: 2514–22.
4. Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593–9.
5. Gerber H, Kowalski J, Sherman D, et al. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000;60:6253-8.
6. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007 Apr 26; [Epub ahead of print]
We thank Dr Shoaib for his comments.
In the results we clearly state 'The indication for insertion was based on
the presence of ocular surface changes and poor tear film meniscus, with a
previous unsuc- cessful management by lubrication and topical medication
alone. Overall, 18 of the 25 patients had a concurrent systemic disorder
(table 1).'
Schirmer's test is , we believe , a poor test for dry eye in children. It
often r...
We thank Dr Shoaib for his comments.
In the results we clearly state 'The indication for insertion was based on
the presence of ocular surface changes and poor tear film meniscus, with a
previous unsuc- cessful management by lubrication and topical medication
alone. Overall, 18 of the 25 patients had a concurrent systemic disorder
(table 1).'
Schirmer's test is , we believe , a poor test for dry eye in children. It
often results in reflex tearing and is of little clinical value in
children. Tear break up time is only of value if we know what the normal
value is in CHILDREN. This is in fact the subject of our next manuscript
which is in review as I write this. In children under 12 years of age and
over 4 years of age , the non-invasive tear break up time using the
Tearscope ( Keeler , Windsor ,UK) is over 25 seconds ( unpublished data as
yet). So in children we looked at tear meniscus and ocular surface changes
such as PEE. We not only relied on subjective improvement but also
objective signs of improvement of ocular surface changes.
As for the comparison of cases of BKC, we can only comment on our own
paper which Dr Shoaib cites(1) . Please note that the majority of the
children in the 'Punctal Plug' manuscript had a systemic disorder which
led to secondary lid and corneal changes. In the article cited regarding
BKC (1) many of the children had neovascularisation of the cornea and
lubrication is clearly mentioned but not punctual plugs. We clearly state
here in the 'Punctal Plug' article that children who failed lubrication
were offered plugs. None of the cohort from the 2007 manuscript were in
this manuscript.
Finally, it is precisely because children can be so difficult to assess
that there has been no previous manuscript, to the best of our knowledge,
discussing punctual plugs exclusively in children.
1 Jones SM, Weinstein JM, Cumberland P, Klein N, Nischal KK. Visual
Outcome and Corneal Changes in Children with Chronic
Blepharokeratoconjunctivitis. Ophthalmology 2007;114:2271-2280
Dear Editor,
We read with interest the article by Gupta and colleagues describing their findings in an investigation of the utility loss associated with glaucoma. When considered in light of previous investigations this work makes an important contribution to our limited understanding of the influence of culture, socio-economic status, and ethnic background on health state preference. It is particularly gratifying...
Dear Editor
We read with interest the letter by Prakash et al.[1] concerning residual cortical lens matter in the anterior chamber after phacoemulsification. This was noted ten days post-operatively and was promptly removed to alleviate a secondary rise in intraocular pressure (IOP). We would like to share our experience of an unusual case of retained lens matter presenting thirteen months post phacoemulsif...
Dear Editor,
We read with interest the recently published paper by Manzano et al. titled ‘Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)’. The authors used topical eyedrop application of either saline or bevacizumab in a rat model of corneal neovascularization, with apparent moderate success. Furthermore, in their discussion, they mention that there was incomplete inhibition of th...
We thank Drs Hanovar and Ali for their comments. The main impetus for publishing this data was to show that children are NOT prone to infections with this strategy. In fact while steroid injections were given in cases of severe corneal neovascularisation such as K.I.D. syndrome and ectodermal hypoplasia , the fact that no child got a canaliculitis or other infection even when steroids were used, re-affirms that infection i...
Dear Editor,
We read with interest the article by Kapetanakis et al.[1] The authors presented a systemic review of published population-based surveys to provide estimates of global and regional prevalence of primary open- angle glaucoma (POAG). The authors claimed that this review provided the most precise estimates of POAG prevalence thus far, as they adopted a more "inclusive" approach, compared to previous re...
Dear Editor
The authors of this article (Tan J C H, and Hitchings R. Non-penetrating glaucoma surgery: the state of play. Br J Ophthalmol 2001;85:234-237) should be commended on attempting to tackle this issue. Nevertheless we do feel that their fundamental points and principal arguments merit reconsideration.
The authors state categorically that "long term outcomes do not exit for the newer...
Dear Editor,
I should like to congratulate the authors for the article citing the original publication on peripheral fading by Troxler (1804). However, as editor of the website on the work of the Swiss philosopher Ignaz Paul Vital Troxler (1780-1866) who started as physician and ophthalmologist before engaging in research on anthropological and political subjects, I regret that after 201 years, the publication of 18...
Dear Editor
I read with great interest your case report on the leech bite to the eye sustained by a 4 year old girl in Germany - in particular that infestation of the human eye is very rare (“To our knowledge only one case is described in the literature”). While this may indeed be the case in Europe, here in Tasmania, the southernmost state of Australia, this event is evidently much more common and occasions a lot...
Dear Editor
We have read Manzano et al’s insightful paper[1] with interest and appreciated the comments concerning the inhibitory effects of bevacizumab on corneal neovascularisation (NV). However, the manuscript had some important aspects that need to be clarified. Cumulative data from numerous basic and clinical studies strongly implicates the central role of VEGF in ocular and corneal angiogenesis. Binding all free-ci...
We thank Dr Shoaib for his comments. In the results we clearly state 'The indication for insertion was based on the presence of ocular surface changes and poor tear film meniscus, with a previous unsuc- cessful management by lubrication and topical medication alone. Overall, 18 of the 25 patients had a concurrent systemic disorder (table 1).' Schirmer's test is , we believe , a poor test for dry eye in children. It often r...
Pages